About Pelage Pharmaceuticals
Pelage Pharmaceuticals is a private company based in Los Angeles, California. It has reported $150,749,975 raised in three offerings on Form D since June 2023. Its chief executive is Daniel Gil.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2025 | Nov 24, 2025 | $119,999,987fully sold | 5 | $23.9M | EquityRule 506(b) | Form D ↗ |
| Aug 12, 2024 | Aug 23, 2024 | $13,999,994fully sold | 6 | $2.3M | EquityRule 506(b) | Form D ↗ |
| Jun 20, 2023 | Jun 28, 2023 | $16,749,994fully sold | 6 | $2.7M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $150,749,975 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Pelage Pharmaceuticals's Form D filed Nov 24, 2025.
CF
Cathy Friedman
Director
NW
Nathan Wheeler
Executive officer
WL
William Lowry
Executive officer and director
CW
Christina Weng
Executive officer
DG
Daniel Gil
Chief Executive Officer and director
RH
Richard Heyman
Director
Earlier filings also listed Heather Christofk (executive officer, last listed Aug 2024).